

Case 3

- 58-year-old woman
- Presented with incidental finding of bilateral lung lesions when undergoing preoperative CT for hernia repair
 - Feels well without symptoms
- Past medical, family, and social history
 - Hypertension on a thiazide diuretic
 - Distant ex-smoker (10 pack years) and stopped smoking 25 years ago
- Physical examination
 - Current weight: 120 lbs
 - ECOG PS 1

Case 3 (Cont.)

- Diagnostic workup
 - CT of thorax discovered an R lower lobe mass
 - CT of abdomen showed an R adrenal metastasis and bone windows, suggesting bone metastases
 - MRI of brain negative for brain metastases
- Final pathology: consistent with adenocarcinoma, TTF1-, CDX2+, intestinal type
 - Metastatic stage IV
- PD-L1 expression by IHC: 40%
- NGS: no actionable mutations

- **What treatment options should be considered?**

Immunotherapy Options for Advanced NSCLC with PD-L1 Expression $\geq 1\%$ or $\geq 1\%$ to 49% (NCCN Cat 1)⁹


Regimen Trial	IPI/NIVO CHECKMATE 227 ¹ n=396	IPI/NIVO+CT CHECKMATE 9LA ² n=204	PEM+PC(AD) KEYNOTE-021 ³ N=39	PEM+PC(AD) KEYNOTE-189 ⁴ n=128	PEM+CP(SC) KEYNOTE-407 ⁵ n=103	ATEZO+BCP IMpower 150 ⁶ n=359	CEM+CT EMPOWER-Lung 3 ⁷ n=114	TREM/DURV+CT POSEIDON ⁸ n=338
NCCN status	NCCN Cat 1	NCCN Cat 1	NCCN Cat 1 Preferred	NCCN Cat 1 Preferred	NCCN Cat 1 Preferred	NCCN Cat 1 AD only	NCCN Cat 1	NCCN Cat 1 AD only
PD-L1% parameter	TPS $\geq 1\%$ ‡	TPS $\geq 1\%$ ‡	TPS $\geq 1\%$ ¶	TPS $\geq 1\%$ - 49% ¶	TPS $\geq 1\%$ - 49% ¶	TC/IC 0-3 †¶	TPS $\geq 1\%$ - 49%¶	TC 1-2 ¶
ORR,%	36%	87%	61%	50%	54.40%	55%*	43.0%	38.8%
Median DoR, mo	24.5	11.8	NR	13.6	11.1	10.8*	16.4*	9.5
Median OS, mo	17.1 (HR: 0.78)	15.8 (HR:0.73)	40.9 (HR:0.84)	21.8 (HR:0.65)	18.0 (HR 0.61)	19.2 (HR:0.78)* 18.9 (HR:0.69) PD-L1 TPS $\geq 1\%$	23.2 (HR: 0.50)	14 (HR:0.77)

*Value represents all PD-L1 subtypes combined; ¶By PD-L1 22C3 assay; †By PD-L1 SP142 IHC assay; ‡By PD-L1 28-8 IHC assay; ¶ By PD-L1 SP263 IHC assay. AD, adenocarcinoma; Atezo, atezolizumab; BCP, bevacizumab + carboplatin + paclitaxel; cat, category; CEM, cemiplimab; CP, paclitaxel/nab paclitaxel, carboplatin; CT, chemotherapy; DoR, duration of response; DURV, durvalumab; HR, hazard ratio; IC, immune cells; IPI, ipilimumab; mo, month; NCCN, National Comprehensive Cancer Network; NIVO, nivolumab; NR, not reported; OS, overall survival; ORR, objective response rate; PC, pemetrexed/carboplatin; PEM, pembrolizumab; PFS, progression-free survival; SC, squamous cell; TC, tumor cells; TPS, tumor proportion score; TREM, tremelimumab.

1. Ramalingam SS, et al. WCLC 2023. Abstract OA14.03. 2. Reck M, et al. ASCO 2024. Abstract 8560. 3. Awad MM, et al. *J Thorac Oncol.* 2021;16:162-168. 4. Garassino MC, et al. *J Clin Oncol.* 2023;41:1992-1998. 5. Novello S, et al. *J Clin Oncol.* 2023;41:1999-2006. 6. Socinski MA, et al. *J Thorac Oncol.* 2021;16:1909-1924. 7. Makharadze T, et al. *J Thorac Oncol.* 2023;18:755-768. 8. Johnson ML, et al. *J Clin Oncol.* 2023;41:1213-1227. 9. Riely GJ, et al. NCCN Guidelines. Non-Small Cell Lung Cancer (Version 3.2023). NCCN.org.

KEYNOTE-189: 5-Year Outcomes


ITT



No. at risk:

	0	12	24	36	48	60	72
Pembrolizumab + chemo	410	283	184	126	95	77	0
Placebo + chemo	206	98	55	34	27	22	0


PD-L1 TPS 1%-49%



No. at risk:

	0	12	24	36	48	60	72
Pembrolizumab + chemo	128	91	56	36	28	25	0
Placebo + chemo	58	29	18	9	5	4	0

First-Line Nivolumab/Ipilimumab + 2 Cycles of CT for Advanced NSCLC with PD-L1 1% to 49% (CheckMate 9LA)



Outcomes: PD-L1≥1%-49%	Nivo/Ipi + CT (n=127)	CT (n=106)
ORR, % (n)	39.4	24.5
mDOR, mo (95% CI)	10.0 (6.5-13.2)	5.6 (3.9-15.2)


127 (0)	116 (0)	102 (0)	88 (0)	80 (0)	56 (8)	33 (27)	17 (42)	5 (54)	0 (59)	0 (59)
106 (0)	95 (0)	80 (0)	60 (0)	46 (0)	30 (5)	20 (10)	10 (18)	4 (24)	0 (28)	0 (28)

mDoR, median duration of response.

Paz-Ares L, et al. *Lancet Oncol.* 2021;22:198-211.

Cemiplimab ± Chemotherapy for NSCLC: EMPOWER-Lung 3

All patients (N=466)




	Cemiplimab + chemo (OS events/patients)	Placebo + chemo (OS events/patients)	Hazard ratio (95% CI)
All patients	180/312	111/154	0.65 (0.51-0.82)
Age group			
<65 years	100/184	70/94	0.53 (0.39-0.72)
≥65 years	80/128	41/60	0.81 (0.55-1.18)
Sex			
Male	155/268	92/123	0.55 (0.42-0.71)
Female	25/44	19/31	0.98 (0.54-1.78)
Race			
White	155/267	102/138	0.61 (0.47-0.78)
Non-White	25/45	9/16	0.81 (0.38-1.74)
Histology			
Squamous	79/133	47/67	0.61 (0.42-0.87)
Nonsquamous	101/179	64/87	0.64 (0.47-0.88)
PD-L1 level			
<1%	66/95	34/44	0.94 (0.62-1.42)
1-49%	62/114	43/61	0.50 (0.34-0.74)
≥50%	52/103	34/49	0.56 (0.36-0.86)

EMPOWER-Lung 3: OS and PFS by Histology

Subgroup	OS Events			PFS Events			ORR %
	Cemiplimab + Chemotherapy vs Placebo + Chemotherapy	Median OS (months)	OS HR (95% CI)	Cemiplimab + Chemotherapy vs Placebo + Chemotherapy	Median PFS (months)	PFS HR (95% CI)	
Squamous PD-L1: <1% (n=54)	23/38 vs 13/16	21.9 vs 16.7	0.60 (0.30-1.20)	31/38 vs 14/16	8.3 vs 6.1	0.70 (0.37-1.32)	50.0 vs 31.3
Squamous PD-L1: 1-49% (n=81)	31/53 vs 19/28	23.2 vs 8.6	0.52 (0.29-0.92)	45/53 vs 25/28	6.7 vs 4.2	0.55 (0.33-0.90)	43.4 vs 25.0
Squamous PD-L1: ≥50% (n=65)	25/42 vs 15/23	22.2 vs 15.1	0.77 (0.40-1.45)	33/42 vs 18/23	8.3 vs 5.5	0.51 (0.28-0.92)	47.6 vs 26.1
Non-Squamous PD-L1: <1% (n=85)	43/57 vs 21/28	9.6 vs 13.0	1.26 (0.74-2.12)	46/57 vs 25/28	5.2 vs 4.3	0.79 (0.49-1.30)	22.8 vs 14.3
Non-Squamous PD-L1: 1-49% (n=94)	31/61 vs 24/33	23.2 vs 12.0	0.48 (0.28-0.82)	42/61 vs 30/33	8.5 vs 6.2	0.42 (0.26-0.69)	42.6 vs 15.2
Non-Squamous PD-L1: ≥50% (n=87)	27/61 vs 19/26	24.8 vs 14.4	0.42 (0.23-0.76)	37/61 vs 21/26	12.5 vs 5.2	0.46 (0.27-0.80)	57.4 vs 26.9


Durvalumab ± Tremelimumab in Combination with Chemotherapy (POSEIDON)

FDA approved November 10, 2022



No. at risk:


D + CT	338	296	247	212	176	142	126	112	97	85	81	51	33	15	5	0	0
CT	337	284	236	204	160	132	111	91	72	62	52	38	21	13	6	0	0





No. at risk:

T + D + CT	338	298	256	217	183	159	137	120	109	95	88	64	41	20	9	0	0
CT	337	284	236	204	160	132	111	91	72	62	52	38	21	13	6	0	0

POSEIDON: OS in Patients With PD-L1 $\geq 1\%$ or Nonsquamous Histology




First-Line Nivolumab+Ipilimumab Versus CT for Advanced or Metastatic NSCLC and PD-L1 $\geq 1\%$ (CheckMate 227 Part 1)



Outcomes	Nivolumab/Ipilimumab (n=396)	Nivolumab (n=396)	Chemotherapy (CT) (n=397)	Outcomes	Nivolumab/ Ipilimumab (n=396)	Nivolumab (n=396)	Chemotherapy (CT) (n=397)
ORR, % (95% CI)	35.9 (31.1-40.8)	27.5 (23.2-32.2)	30.0 (25.5-34.7)	ORR, % (n)	36 (144)	28 (109)	30 (118)
mDOR, mo (95% CI)	23.2 (15.2-32.2)	15.5 (12.7-23.5)	6.2 (5.6-7.4)	mDOR, mo (95% CI)	24.5 (15.5-34.5)	15.5 (12.7-20.8)	6.7 (5.6-7.6)

No data available for PD-L1 1%-49% group

CheckMate 227 Part 1: OS in Patients With PD-L1 $\geq 1\%$ and Nonsquamous Histology




Number of patients at risk

Nivolumab + ipilimumab	278	243	213	193	175	156	142	125	119	111	102	96	95	93	91	87	82	67	46	17	3	0
Nivolumab	278	233	216	194	161	150	135	115	106	98	93	88	87	77	72	62	59	46	23	10	4	0
Chemotherapy	279	255	227	189	167	148	131	115	104	92	81	76	71	69	65	60	57	41	21	6	2	0

FDA Pooled Analysis

Exploratory Questions: NSCLC PD-L1 1-49%

FDA



RCT Leading to Approval

Experimental Arm*†

IO alone

- KEYNOTE-042
- CheckMate 227

Pembro
Nivo + ipi


Chemo-IO

- KEYNOTE-189
- KEYNOTE-407
- KEYNOTE-021 (Cohort G)
- IMpower150
- IMpower130
- CheckMate 9LA

Pembro + chemo
Pembro + chemo
Pembro + chemo
Atezo + bev + chemo
Atezo + chemo
Nivo + ipi + chemo

*Chemo: platinum doublet; †Control arm in all trials was platinum-doublet chemo, except for IMpower150, which was bevacizumab + platinum-doublet chemo. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; IO, immuno-oncology; RCT, randomized controlled trial.

FDA Pooled Analysis of First-Line Chemo-IO vs IO in Advanced NSCLC with PD-L1 1% to 49%: Exploratory OS



Summary

- No clear role for single agent immunotherapy
- Immunotherapy + chemotherapy or quadruplet regimens may be used